Drugs / CPCB-RPE1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02590692 | Feb 2016 → Jul 2019 | diffuse secondary choroid atrophy, dry age related macular degeneration | Regenerative Patch Technologies, LLC | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-06-28 | Regenerative Patch Technologies, LLC | Results Regenerative Patch Technologies Provides Update on Phase 1/2a Clinical Trial of Stem Cell-Engineered Implant for the Treatment of Dry Age-Related Macular Degeneration regenerativepatch.com ↗
Regenerative Patch Technologies LLC (RPT) announced today the presentation of results from its Phase 1/2a clinical trial of the CPCB-RPE1 implant for advanced, dry age-related macular degeneration. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-06-28 | Regenerative Patch Technologies, LLC | Regenerative Patch Technologies Provides Update on Phase 1/2a Clinical Trial of Stem Cell-Engineered Implant for the Treatment of Dry Age-Related Macular Degeneration regenerativepatch.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CPCB-RPE1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02590692 ↗ |
| Modality | Cell therapy | “Human Embryonic Stem Cell-Derived RPE Cells” NCT02590692 ↗ |
| Route | Other | “Subretinal implantation of CPCB-RPE1” NCT02590692 ↗ |